Peptide-mediated immunosuppression

American Journal of Therapeutics

Volumn 12, Issue 6, 2005, Pages 592-599

  Zang, Weiping ^a   Murphy, Barbara ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; Major histocompatibility complex; Peptides; T cell

Indexed keywords

AUTOANTIGEN; CASPASE; CYCLOSPORIN; CYTOKINE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; HLA B ANTIGEN; HLA B2702.75 84 ANTIGEN; HLA B7.75 84 ANTIGEN; HLA DQ 65 79 ANTIGEN; HLA DQ ANTIGEN; HLA DQA 0101 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 0501 ANTIGEN; HLA DQB1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; PEPTIDE DERIVATIVE; SYNTHETIC PEPTIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGRAFT; ALLOIMMUNITY; ALPHA CHAIN; APOPTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; MIXED LYMPHOCYTE REACTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DQ ANTIGENS; HUMANS; IMMUNOSUPPRESSION; MICE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 28044433622     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000178766.60234.e2     Document Type: Conference Paper

References (29)

1. Sayegh MH, Carpenter MH. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 1996;13:221-229.
2. Murphy B, Krensky AM. HLA-derived peptides as novel immunomodulatory therapeutics. J Am Soc Nephrol. 1999;10:1346-1355.
3. Reinherz EL, Tan K, Tang L, et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science. 1999;286:1913-1925.
4. Sloan-Lancaster J, Evavold B, Allen P. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 1993;363:156-159.
5. Murphy B, Sayegh MH. Why do we reject a graft? Mechanisms of recognition of transplantation. Transplant Rev. 1996;10:150-159.
6. Clayberger C, Lyu SC, Pouletty P, et al. Peptides corresponding to T cell receptor HLA contact regions inhibit class I restricted immune responses. Transplant Proc. 1993;25:477-478.
7. Clayberger C, Krensky A. Immunosuppressive peptides corresponding to MHC class I sequences. Curr Opin Immunol. 1995;7:644-648.
8. Willets IE, Tam PKH, Morris PJ, et al. Treatment with an HLA-peptide and cyclosporine A prolongs rat small bowel allograft survival. J Pediatr Surg. 1997;32:469-472.
9. Woo J, Gao L, Cornejo M-C, et al. A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Transplantation. 1995;60:1156-1163.
10. Nisco S, Vriens P, Hoyt G, et al. Induction of allograft tolerance in rats by an HLA-class I derived peptide and cyclosporine. Am J Immunol. 1994;152:3786-3792.
11. Buelow R, Veyron P, Clayberger C, et al. Prolongation of skin allograft survival in mice following administration of ALLOTRAP. Transplantation. 1995;59:455-460.
12. Murphy B, Kim KS, Buelow R, et al. Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis to Fischer 344 model of chronic rejection. Transplantation. 1997;64:14-19.
13. Giral M, Cuturi MC, Nguyen JM, et al. Decreased cytotoxic activity of natural killer cells in kidney allograft recipients treated with human HLA-derived peptide. Transplantation. 1997;63:1004-1011.
14. Noessner E, Goldberg JE, Naftzger C, et al. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J Exp Med. 1996;183:339-348.
15. Iyer S, Woo J, Cornejo MC, et al. Characterization and biological significance of immunosuppressive peptide D2702.75-84 (E-V) binding protein. J Biol Chem. 1998;273:2692-2697.
16. Grassy G, Calas B, Yasri A, et al. Computer-assisted rational design of immunosuppressive compounds. Nat Biotechnol. 1998;16:748-752.
17. Iyer S, Kontoyiannis D, Chevrier D, et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem. 2000;275:17051-17057.
18. Murthy S, Flanigan A, Coppola D, et al. RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002;51:522-531.
19. Bourreille A, Doubremelle M, de la Bletiere DR, et al. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand J Gastroenterol. 2003;38:526-532.
20. Li W, Iyer S, Lu L, et al. Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. Transpl Int. 2003;16:849-856.
21. Boytim ML, Lyu SC, Jung R, et al. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: functional similarities but mechanistic differences with the immunosuppressive drug rapamycin. J Immunol. 1998;160:2215-2222.
22. Murphy B, Magee CC, Alexander SI, et al. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest. 1999;103:859-867.
23. Ling X, Kamangar S, Boytim ML, et al. Proliferating cell nuclear antigen as the cell cycle sensor for an HLA-derived peptide blocking T cell proliferation. J Immunol. 2000;164:6188-6192.
24. Dong C, Lyu SC, Krensky AM, et al. DQ 65-79, a peptide derived from HLA class II, mimics p21 to block T cell proliferation. J Immunol. 2003;171:5064-5070.
25. Reinherz EL, Tan K, Tang L, et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science. 1999;286:1913-1921.
26. Murphy B, Yu J, Jiao Q, et al. A novel mechanism for the immunomodulatory functions of class II MHC-derived peptides. J Am Soc Nephrol. 2003;14:1053-1065.
27. Murphy B, Auchincloss H Jr, Carpenter CB, et al. T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation. 1996;61:1133-1137.
28. Jenkins MK, Pardoll DM, Mizuguchi J, et al. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol Rev. 1987;95:113-135.
29. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol. 1998;8:267-271.